Akebia Therapeutics (AKBA) Capital Expenditures (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Capital Expenditures data on file, last reported at $749000.0 in Q1 2026.

• On a quarterly basis, Capital Expenditures rose 4061.11% year-over-year to $749000.0 in Q1 2026; TTM through Mar 2026 was $3.4 million, a 375.51% increase from a year earlier, with the FY2025 full-year figure at $2.6 million, up 521.54% from the prior year.
• Capital Expenditures for Q1 2026 stood at $749000.0, down from $2.4 million in the prior quarter.
• Over the last five years, Capital Expenditures for AKBA reached as high as $10.1 million in Q3 2022 and fell as low as -$8.2 million in Q4 2023.
• Historically, Capital Expenditures has averaged $178937.5 across 5 years, with a median of $101500.0 in 2025.
• Across the five-year window, Capital Expenditures slumped 191.4% in 2022 and jumped 4061.11% in 2026, its largest moves.
• Year by year, Capital Expenditures stood at $10.1 million in 2022, then sank by 180.73% to -$8.2 million in 2023, then surged by 92.01% to -$653000.0 in 2024, then jumped by 467.69% to $2.4 million in 2025, then sank by 68.8% to $749000.0 in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $749000.0 in Q1 2026, $2.4 million in Q4 2025, and $77000.0 in Q3 2025.